These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20166183)

  • 1. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.
    Golden-Mason L; Madrigal-Estebas L; McGrath E; Conroy MJ; Ryan EJ; Hegarty JE; O'Farrelly C; Doherty DG
    Gut; 2008 Aug; 57(8):1121-8. PubMed ID: 18372499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
    Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
    Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
    Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.
    Kronenberger B; Herrmann E; Hofmann WP; Wedemeyer H; Sester M; Mihm U; Ghaliai T; Zeuzem S; Sarrazin C
    J Leukoc Biol; 2006 Aug; 80(2):298-308. PubMed ID: 16735696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
    Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
    Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.
    Bonorino P; Ramzan M; Camous X; Dufeu-Duchesne T; Thélu MA; Sturm N; Dariz A; Guillermet C; Pernollet M; Zarski JP; Marche PN; Leroy V; Jouvin-Marche E
    J Hepatol; 2009 Sep; 51(3):458-67. PubMed ID: 19596474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV.
    Zarife MA; Reis EA; Carmo TM; Lopes GB; Brandão EC; Silva HR; Santana N; Martins-Filho OA; Reis MG
    J Med Virol; 2009 Jan; 81(1):49-59. PubMed ID: 19031471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection.
    Titanji K; Sammicheli S; De Milito A; Mantegani P; Fortis C; Berg L; Kärre K; Travi G; Tassandin C; Lopalco L; Rethi B; Tambussi G; Chiodi F
    Immunology; 2008 Feb; 123(2):164-70. PubMed ID: 17627773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
    He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between the percent of CD3- CD56+ cells and NK precursor function.
    Gharehbaghian A; Donaldson C; Newman J; Bannister G; Bradley BA
    Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):167-75. PubMed ID: 17237569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
    Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C in the advanced adult and elderly subjects.
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells prevalence, subsets and function in viral hepatitis C.
    Zeromski J; Mozer-Lisewska I; Kaczmarek M; Kowala-Piaskowska A; Sikora J
    Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):449-55. PubMed ID: 21972016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.
    Vrolijk JM; Kwekkeboom J; Janssen HL; Hansen BE; Zondervan PE; Osterhaus AD; Schalm SW; Haagmans BL
    J Infect Dis; 2003 Nov; 188(10):1528-32. PubMed ID: 14624378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.
    Morishima C; Paschal DM; Wang CC; Yoshihara CS; Wood BL; Yeo AE; Emerson SS; Shuhart MC; Gretch DR
    Hepatology; 2006 Mar; 43(3):573-80. PubMed ID: 16496327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.